SynthesisFrontiers in immunology2026
What are the beneficial treatment strategies in maintaining T lymphocyte subsets after cancer surgery? A systematic review and network meta-analysis.
Synthesis in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Perioperative alterations in T lymphocyte subsets significantly impact tumor recurrence and postoperative recovery; therefore, identifying optimal strategies to maintain these immune parameters is essential for improving cancer surgery outcomes. The immunomodulatory effects of different tumor therapies, especially those on key T cell subsets, still lack systematic comparisons. Objective: This study aims to systematically evaluate the impact of various treatment strategies (including systemic anti-cancer therapy (SACT), nutritional support, anesthesia, analgesia, and other methods) on key immune parameters (CD3 Methods: Systematic reviews and network meta-analyses were conducted on randomized controlled trials included in the PubMed, Embase and Cochrane CENTRAL databases using the PRISMA guidelines. Pairwise meta-analyses and network meta-analyses were completed using RevMan 5.3 and the gemtc package of R software. The efficacy was ranked by the area under the cumulative ranking curve (SUCRA), and the quality of the studies was evaluated using the Cochrane Risk of Bias Tool 2.0 and the Newnews-Ottawa Scale. Results: The analysis included 82 RCTs. In maintaining T lymphocyte subsets, immune-enhanced enteral nutrition combined with neoadjuvant chemotherapy (IEN+NACT), targeted therapy (TD), the Enhanced Recovery After Surgery (ERAS) protocol, anesthesia techniques incorporating Transcutaneous Electrical Acupoint Stimulation (TEAS), and analgesia with Dexmedetomidine (DEX) ranked as the most effective strategies, with IEN+NACT showing the greatest improvement in CD4+ counts (SMD 12.33, 95% CI 7.44-17.04). Safety analysis indicated that the risks associated with these top-ranking interventions were acceptable. Conclusion: This network meta-analysis determined that for tumor surgery patients, the perioperative management plan should combine a multimodal strategy of IEN + NACT, ERAS, TD, TEAS and DEX to maintain postoperative T lymphocyte homeostasis and thereby protect immune function. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD420251233455, identifier CRD420251233455.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.